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Abstract
Electrochemotherapy is a local treatment of cancer employing electric pulses to
improve transmembrane transfer of cytotoxic drugs. In this paper we discuss
electrochemotherapy from the perspective of biomedical engineering and review
the steps needed to move such a treatment from initial prototypes into clinical
practice. In the paper also basic theory of electrochemotherapy and preclinical studies
in vitro and in vivo are briefly reviewed. Following this we present a short review of
recent clinical publications and discuss implementation of electrochemotherapy into
standard of care for treatment of skin tumors, and use of electrochemotherapy for
other targets such as head and neck cancer, deep-seated tumors in the liver and
intestinal tract, and brain metastases. Electrodes used in these specific cases are
presented with their typical voltage amplitudes used in electrochemotherapy. Finally,
key points on what should be investigated in the future are presented and discussed.
Keywords: Electroporation, Electrochemotherapy, Preclinical results, Clinical studies,
Electrochemotherapy for skin and superficial tumors, Electrochemotherapy for visceral
and deep-seated tumors

Introduction
Electrochemotherapy is a local treatment of cancer which combines the use of a medical device with pharmaceutical agents to achieve local tumor control in solid cancers.
The procedure consists of applying short high-intensity pulsed electric fields to cells,
in response to which, the plasma membrane’s permeability to various molecules transiently increases. This facilitates cellular uptake of cytotoxic agents, thus increasing their
cytotoxicity [1-4]. The treatment is based on the phenomenon termed electroporation,
which occurs, when externally delivered electric field induces a sufficiently large transmembrane voltage. Electroporation is, in addition to its use in electrochemotherapy,
used also as non-viral gene delivery method to cells in vitro and in vivo – gene electrotransfer [5,6]. Furthermore, electroporation as sole modality can be used as tumor ablation in the form of irreversible electroporation, also referred to as non-thermal
irreversible electroporation [7-14].
Electrochemotherapy uses electroporation to allow increased uptake of chemotherapeutic drugs into tumor cells [2,15]. Since the initial research in vitro, which was performed more than 20 years ago, electrochemotherapy has gone through extensive basic
research on the mechanisms of its action, the required electric field, pulse parameters
[16] and sequences for successful treatment, screening of appropriate drugs for use
© 2014 Miklavčič et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
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with electric pulses [17,18], in vivo studies on different animal models [19], as well as
clinical trials in cutaneous and subcutaneous tumors [19,20] and deep-seated tumors
[21-23]. The aim of this review is to give the reader a concise overview over the development of this biomedical engineering-based cancer treatment modality. Its foundation
and discussion is critical to guide the development of electrochemotherapy, as adequate
preclinical evidence for any kind of medical treatment requires significant time and financial resources. This present paper provides an overview of the current status of
electrochemotherapy and sets the groundwork for discussion on further development
and standardization of the technique in relation to other local and/or ablation treatment modalities.
This review is divided into several sections comprising the following topics:
 Overview of preclinical research and clinical data on use of electrochemotherapy in

treatment of cutaneous and subcutaneous tumors. Implementation into standard of
care, focusing on cutaneous and subcutaneous metastases.
 Other uses of electrochemotherapy, such as treatment of visceral and deep-seated
tumors.
 The last section outlines the challenges for future studies which need to be addressed,
taking into account important aspects of cancer treatment, such as improvement in
patient’s quality of life and in time to progression or overall survival.
Physical/theoretical background of electrochemotherapy

Electrochemotherapy relies on using hydrophilic drugs in combination with application
of high-voltage electric pulses applied to tumors. The two drugs that have been used
most often in electrochemotherapy are bleomycin (BLM), and cisplatin (cis-diamminedichloroplatinum (II) – CDDP). Both of these drugs are membrane low- or nonpermeable, and their intracellular target is DNA [24]. The applied electric pulses are
most commonly delivered in trains of eight 100-μs-long pulses. By using these electric
pulses, the efficacy of the chemotherapeutic drugs is potentiated significantly. The potentiation is most expressed for BLM [2] and CDDP [25]. Potentiation of other drugs
has also been studied [17,18] but proved to be much lower or insignificant (Table 1).
Upon the application of external electric pulses to cells (either in a culture medium,
or in tissue), the electric field causes relocation of charges on the cell membrane. This
causes the buildup of transmembrane voltage – termed induced transmembrane voltage, which is superimposed to the cells’ normal resting transmembrane voltage (or resting membrane potential, as it is termed in physiology literature). The increase in
transmembrane voltage follows Schwann’s equation [34,35], and in areas, where transmembrane voltage exceeds a certain voltage, a sufficiently strong electric field through
the membrane is established leading to pore formation which allows the passage of
water, charged molecules, as well as larger molecules. Although these pores are too
small and short-lived to be observed using conventional or electron microscopy, indirect evidence supporting their existence comes from simulations of lipid bilayers using
molecular dynamics simulations [36-38].
Cellular membranes can remain permeable, for large and charged molecules, for minutes after the external electric field delivery ceases [4,39,40]. The mechanism of membrane “resealing” or repair requires active cellular mechanisms and therefore also energy
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Table 1 Summary of drugs tested for in vitro and in vivo potentiation in combination
with electroporation pulses
Drug tested

In vitro potentiation

Bleomycin

Yes; 100–5000-fold [1,17,18,26-28]

In vivo potentiation
Yes

Cisplatin

Yes; 1.8–12.2-fold [17,18,28,29]

Yes [28-30]

Calcium

Yes; more hundred-fold [31,32]

Yes [31]

Netropsin

Yes; 200-fold [1]

–

Carboplatin

Yes; 1.6–13-fold [17,18,27,29]

–

2-N-methyl-9-hydroxy-ellipticinium (NMHE)

Yes; 4-fold [1]

–

Vincristine

Yes; 1.3–3.4-fold [18]

–

ActiNomycin D

Yes; 2–3-fold [1]

–

Cytarabine

Yes; 2-fold [18]

–

Oxaliplatin

Yes [29]

–

Platinum (II) complex 3P-SK

Yes [29]

Yes [29]

Platinum (II) complex PtAMP

Yes [29]

–

Mitomycin C

Yes but low; 1.3–1.4-fold [18,33]

–

Vinblastine

Yes but low; 1.1–1.3-fold [18]

–

5-fluorouracil

No or low; 1.25-fold [18,26]

–

Paclitaxel

No or low; 1.3-fold [17,18]

–

Doxorubicin

No or low; 0.67–2-fold [17,18]

–

Nimustine hydrochloride (ACNU)

No [27]

–

Methotrexate

No [1]

–

9-OH-ellipticine

No [1]

–

Didemnin B

No [1]

–

Melphalan

No [1]

–

Mithramycin

No [1]

–

Taxotere

No [1]

–

DauNorubicin

No [17]

–

Adriamycin

No [32]

No [28]

Etoposide

No or ND [17,18,27]

–

Ancitabine

ND [18]

–

Gemcitabine

ND [18]

–

ND drug was tested but the potentiation could Not be determined due to methodological limitations.
– Not tested.

[41]. A possible explanation of the comparatively long-term permeability of cell membranes is chemical alteration of membrane lipids [42-44]. In order to successfully, and
reproducibly achieve cell membrane electroporation, which is the prerequisite for
successful electrochemotherapy, appropriate pulse generators are needed. Initially,
capacitor discharge pulse generators were used, but later square wave generators
became the most prominent as they provide better reproducibility of pulses and
control of electroporation [45].
Preclinical research and electrochemotherapy mechanisms

Introduction of electrochemotherapy into clinical trials and nowadays into clinical
practice is based on extensive preclinical data, on its effectiveness on different tumors
and on solid evidence of its mechanisms of action. Several mechanisms of action have
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already been identified: increased membrane permeability and intracellular drug accumulation; vascular effects; and involvement of immune response.
The first and the predominant one is increased cellular uptake of BLM and CDDP, by
exposure of cells or tumors to electric field. Increased cytotoxicity of BLM or CDDP
was demonstrated in vitro, with several fold potentiation [2,18,25] (Table 1), as already
mentioned above. The in vitro data were confirmed and elaborated in vivo on different
animal tumor models [4,46-49]. Sufficient drug accumulation in cells is one of the most
prominent underlying mechanisms responsible for effective electrochemotherapy
[2,30,50]. Since the intracellular drug accumulation due to membrane permeabilization
is a consequence of exposure of the cells to sufficiently high local electric field, therefore adequate electric field distribution in the tumors needs to be established [51,52].
All these preclinical data on the pharmacological and physical parameters needed for
effective electrochemotherapy have translated into clinical use of electrochemotherapy.
Currently, BLM is predominantly used in electrochemotherapy, based on higher potentiation of its cytotoxicity. However, the use of CDDP still remains to be fully explored. CDDP namely has the advantage of being effective already on its own, which
however was not further explored after the initial clinical study [53]. Namely, widespread clinical use of CDDP in standard of care could be augmented by sensitizing specific tumors to CDDP by delivering electric pulses [54]. From the clinical perspective it
is also helpful that there is another drug of choice, when BLM is contraindicated, or
the allowed cumulative dose of BLM is reached [55].
Electrochemotherapy also has two distinct vascular effects. Since the exposure of tumors to electric fields predisposes stromal cells to drug uptake, electrochemotherapy
also has an effect on endothelial cells of tumor vessels. This action leads to endothelial
cell death (apoptosis) and consequently to abrogation of tumor blood flow. This first effect was named vascular disrupting effect of electrochemotherapy [56]. The second effect is the vasoconstricting effect, demonstrated in tumors, and confirmed on normal
and tumor vessels by intravital microscopy [57]. This effect, termed vascular lock, induces prolonged entrapment of the drug within the tumors, providing better action of
BLM or CDDP [58]. However, it also prevents inflow of the drug into tumors, if given
after the delivery of electric pulses.
Evidence for electric pulses and electrochemotherapy actions on tumors exists in
histological, physiological and numerical models [56,58]. Furthermore, it was also observed and demonstrated in clinical cases, where electrochemotherapy was used for the
treatment of bleeding tumors [59,60]. However, relative contributions of vascular disrupting and vasoconstricting action of electrochemotherapy in overall electrochemotherapy effectiveness still remain to be determined. Some clinicians emphasize its
great importance, predominantly in well vascularized tumors. However, vascular disrupting effect is not observed on bigger blood vessels, such as major hepatic arteries
and veins, allowing treatment of tumors in vicinity of them, being the advantage over
radiofrequency ablation which is a thermal ablative technique ineffective along bigger
blood vessels due to the heat sink effect. Safety and efficacy of electrochemotherapy
was recently demonstrated in tumors that were close to bigger vessels and in treatment
of liver metastasis located between the major hepatic vessels [22].
Last but not least, involvement of immune response of the organism after electrochemotherapy was demonstrated to be important. Evidently, due to the heterogeneity of
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tumor cells in the tumors, in relation to their orientation, their size, and uneven drug
distribution in the tumors, not all cells in the tumors can be effectively eradicated by
electrochemotherapy [61]. This is due to the fact that not all the cells can be electroporated and/or the drug is not available to all the cells in the tumor. Both reasons stem
from the inhomogeneity of the tumor [62]. Therefore, similarly as with other physical
methods, e.g. radiotherapy, the remaining fraction of cells, when sufficiently low, can
be eradicated by the effective immune response of the organism. In relation to this, evidence that immune competence of the organism is needed for the complete eradication of
the tumors after electrochemotherapy was provided; namely in immunodeficient organisms the curability rate of the tumors was significantly lower than in immunocompetent
ones [61]. This is thought to be related to antigen shedding after electrochemotherapy
from the destroyed cells, which would activate immune cells within the tumors. Some indications also point to the recruitment of antigen presenting cells and boosting of CD11c
and CD11b cells after electrochemotherapy of melanoma [63,64].
It needs to be stressed however, that the effect of electrochemotherapy is local; limited to the treated nodules, as the neighboring non-treated nodules do not respond. To
gain systemic component some attempts were made to boost the immune response by
cytokines (IL-2, IL-12, IL-15, GM-CSF, TNFα) providing some preclinical and clinical
data on the possibility of combining electrochemotherapy and immunotherapies, to
provide systemic antitumor activity [49,65-69].
Based on the mechanisms of action of electrochemotherapy, antitumor activity
should be observed on all types of tumors tested, regardless of their histological origin.
In fact electrochemotherapy is effective on all tumor types, but the effectiveness seems to
vary somewhat, depending on the tumor type [50]. Also, recent review of clinical data
provided evidence of different level of effectiveness of electrochemotherapy in different
tumor types [20]. Although the underlying mechanisms are still to be fully determined,
several mechanisms were already proposed. The first could be that there is intrinsic variability in tumor cell sensitivity to the drugs [50,68,70], the second that successful membrane permeability to some degree depends on tumor type although being sufficiently
high for cell permeabilization [20,50,71], the third, that drug distribution and thus its
availability in different tumors varies depending on the vascularization of the tumors [58],
and the fourth, that the immunogenicity of the tumors is also involved [68].
Recently an attempt was made to address bioavailability of drug particularly in larger tumors by adding intratumoral delivery of drug in addition to systemic, i.e. intravenous drug
delivery. Based on these results it seems that the variability in response due to pharmacological variances in drug distribution particularly in larger tumors could be circumvented
by intratumoral drug administration [72-74]. Furthermore, the pharmacological in vivo
data in patients need to be obtained in order to verify the drug dosage in the tumors that
is required for effective electrochemotherapy. The drug dosage needed for treatment of
smaller tumors may be lower than for larger ones (more than 2 cm in diameter), as well
as for well vascularized tumors, like hepatocellular carcinoma, vs. metastases of colorectal
carcinoma in liver that are less vascularized. Such studies would also clarify the therapeutic window, namely, is there really only 20 minutes time for the therapy [75] or the
time could be longer; the current recommendations are based on observations of only a
single patient. Gathering such pharmacokinetic and pharmacodynamics data would thus
be of great clinical significance.
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Clinical data on electrochemotherapy
Formation of standard operating procedures

The initial clinical studies that were reporting on electrochemotherapy with BLM or
CDDP, even though using somewhat different protocols, provided sufficient evidence
for safe and effective use of electrochemotherapy, both in human and veterinary oncology [70,76,77]. Another milestone was achieved with preparation of the standard operating procedures (SOP) for electrochemotherapy using the Cliniporator device that
were prepared in 2006 during the ESOPE project (European Standard Operating Procedures of Electrochemotherapy) [78]. The SOP were prepared based on the experience
of the leading European cancer centers on electrochemotherapy [55]. The aim of this
document was to define guidelines for safe and effective use of electrochemotherapy
for treatment of cutaneous and subcutaneous tumors, when using the newly developed
electric pulse generator Cliniporator. In particular, the SOP was aimed at oncologists
that have no or little experience performing electrochemotherapy, and standardizing
the therapeutic procedure. The treatment procedures were described in details, to the
point of all necessary materials, and electrode selection for treatment, in specific clinical situation.
Briefly, in the SOP the decision tree was designed and was to be followed helping clinicians in decisions how to treat the patient, according to the number, size and thickness/depth of nodules to be treated. The limit for recommendation of intratumoral
drug administration was set at the point of 5–7 nodules and tumor nodules up to 2 cm
in diameter. However, on multiple nodules and tumor nodules larger than 0.8 cm, an
intravenous drug administration was recommended. Furthermore, the choice of electrodes was suggested based on the size and the thickness/depth of the tumor nodule.
The superficial and small (up to 1 cm) nodules were recommended to be treated by
plate or needle row electrodes, whereas larger nodules were to be treated by hexagonal
needle electrodes [55,78] (Figure 1). The procedure can be performed both in local or
general anesthesia, which was left to the choice of the treating surgeon, but few and
smaller nodules were recommended to be treated in local, while others in general
anesthesia. The SOP also suggested that electrochemotherapy could be repeated in
consecutive sessions.
The preparation of the SOP was an important step which enabled the spread of the
technology throughout Europe, providing the pulse generator certified for use in patients, standardized electrodes, and simple guidelines for medical doctors on how to
use electrochemotherapy in treatment of superficial tumors [55]. Electrochemotherapy
is being introduced into standard clinical practice in Europe and SOP undoubtedly facilitated its increasing usage in clinics [79]. The number of ongoing clinical trials (currently there are 6 ongoing studies in clinicaltrials.gov, and 5 in clinicaltrialsregister.eu,
however, 3 entries are present in both databases) and the number of published studies
is increasing (Figure 2), confirming the relevance of electrochemotherapy in cancer patient’s care.
Since the technology (electrochemotherapy) has spread throughout Europe, vast
experience on its clinical applications is being gathered. It has expanded to the
point that electrochemotherapy is now being used in different clinical situations,
which were not predicted in the originally published SOP. Therefore, new SOP for
cutaneous and subcutaneous tumors and eventually for deep-seated tumors are needed,
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Figure 1 Fixed geometry electrodes available from IGEA Srl. A) Plate electrodes – recommended
voltage 960 V. B) Linear needle electrodes – recommended voltage 400 V. C) Linear needle electrodes,
front view. D) Hexagonal needle electrodes – recommended voltage 730 V. E) Finger electrodes with
perpendicular needles; distance between rows is 4 mm – recommended voltage 400 V. F) Finger electrodes
with axial needles – recommended voltage 400 V.

in order to assure the effectiveness of the treatment and even more importantly the safety
for the patients.
Implementation of electrochemotherapy into standard of care: focus on cutaneous and
subcutaneous tumors

24
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New treatments provide benefit to the patients but at the same time they can put them
at some new risk. Electrochemotherapy, in addition to already established skin directed
therapies, like surgery, radiotherapy, topical and intralesional therapies, and other ablative techniques, offers itself due to its relative ease being performed on an outpatient

Years
Figure 2 Number of publications on clinical electrochemotherapy over the years.
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basis as well as due to its safety and low toxicity. The feasibility and safety of electrochemotherapy was evaluated in the first few clinical studies on electrochemotherapy
[2,80,81]. Due to good safety and toxicity profile, and only minor side effects, it was
concluded that electrochemotherapy on superficial tumors is a safe treatment
[19,78,82,83]. No serious effects related to electrochemotherapy have ever been reported. However, some minor immediate effect are observed, like minor irritation
and uncomfortable sensation or pain associated with contraction of muscles in the
vicinity of the electrodes that immediately subside after delivery of each electric
pulse if performed in local anesthesia [78,84-86]. In addition, some late effects can
also occur, like slight erythema, edema and sometimes necrosis of the tumor. All
these effects are local, transient, minimal and well tolerated by patients; therefore
electrochemotherapy can be performed in an outpatient setting. However, in some
latest studies on locally advanced and metastatic soft tissue sarcomas [87] and large cutaneous recurrences of breast cancer [88], they observed longer-lasting periods of pain after
electrochemotherapy treatment.
Beside good safety profile, electrochemotherapy on superficial tumors proved to be
effective local tumor treatment. The effectiveness of single-session electrochemotherapy
was recently extensively addressed in systematic review including meta-analysis [20].
After more than two decades of clinical application of electrochemotherapy, there was
an indispensable need to consolidate current experience on electrochemotherapy from
the effectiveness point of view and to establish the actual overall effectiveness of electrochemotherapy derived from data reported in clinical studies to-date. The responses
of 1894 tumors from 44 eligible clinical studies published until October 2011 were included in the evaluation. The data demonstrated that the effectiveness of single-session
electrochemotherapy on cutaneous and subcutaneous tumors is 59.4% for complete
response (CR) and 84.1% for objective response (OR). Furthermore, outcomes of
studies published before and after publication of the SOP were compared. Based
on results obtained, we could presume that SOP improved outcome of electrochemotherapy (see Table 2). Partial and objective rates significantly increased, whereas nonresponse rate significantly decreased. However, CR rate remains almost the same. We
probably cannot ascribe this improvement in electrochemotherapy outcome solely to the
SOP, as other factors like experience gained by clinicians, as well as their training, and
exchange of the experience, definitely contributed their share. Recently, an increasing number of new clinical studies on electrochemotherapy have been published,
after the publication of the meta-analysis review. Therefore, we updated results of
systematic review by including outcomes of 472 tumors from 16 additional studies
published between October 2011 and August 2013 (Table 2). These results confirm
positive influence of SOP on effectiveness of electrochemotherapy on cutaneous
and subcutaneous tumors.
In addition to overall effectiveness of electrochemotherapy, the systematic review [20]
addressed also differences in effectiveness of electrochemotherapy of cutaneous and
subcutaneous tumors in clinical setting due to heterogeneous treatment conditions
(i.e. chemotherapeutic drug, route of drug administration, and tumor type). Equal
effectiveness of electrochemotherapy was demonstrated for BLM and CDDP administered intratumorally. However, significantly higher effectiveness for intratumoral than for
intravenous administration of BLM was established. The results of electrochemotherapy
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Table 2 Response rate of the tumors treated by electrochemotherapy, pooled from
individual studies
Publication
period

No. of
studies

No. of
patients

No. of
tumors

OR (%)

CR (%)

PR (%)

NR (%)

Before SOP

19

175

592

458 (77.4%)a, b

362 (61.1%)

96 (16.3%)c,

ESOPE

1

41

171

145 (84.8%)

126 (73.7%)

19 (11.1%)

26 (15.2%)

After SOP
(Oct 2011)

25

294

1192

1047 (87.8%)a

712 (59.7%)

335 (28.1%)c

145 (12.2%)e

After SOP
(Aug 2013)

41

519

1664

1478 (88.8%)b

1031 (62.0%)

447 (26.9%)d

186 (11.2%)f

d

134 (22.6%)e, f

The studies are grouped in those before, and after the ESOPE study, when the standard operating procedures were
published, in 2006. OR = objective response (complete response + partial response); CR = complete response; PR = partial
response; NR = no response (no change + progressive disease); a, b, c, d, e, f = statistically significant difference (p < 0.001,
Chi-square test).

after the intratumoral or intravenous drug administration basically cannot be compared.
Due to the obvious difference in the drug concentrations in the tumors; after intratumoral
administration higher drug concentration is delivered to the tumor than after intravenous
administration. Currently most of the studies report clinical data after intravenous administration, so there may be imbalance between the two groups that are being compared.
Furthermore, the differences in the response rate may be also due to the difference in the
tumor size treated; tumors that were treated by intravenous route may have been larger,
since the SOP was designed to utilize intravenous route for such situations. Recently it
has been suggested that treatment of larger tumors with combined intravenous and intratumoral drug administration can be used with good success [73]. Future studies should be
designed to evaluate the intratumoral route for larger tumors. Previous clinical [82] and
preclinical [49] studies demonstrated the potential success of such approach.
It has been demonstrated that effectiveness of electrochemotherapy varies with tumor
type [20]. Use of often repeated statement about equal effectiveness of electrochemotherapy, regardless of tumor type based on available clinical results appears to be
unjustified. Among all types of tumors, the highest effectiveness of electrochemotherapy was achieved on basal cell carcinoma and the lowest on squamous cell carcinoma
tumors, presumably because squamous cell carcinoma tumors were usually larger in
size than basal cell carcinoma tumors, and also reflecting the fact that basal cell carcinomas tend to recur and metastasize at a lower rate than all other skin tumors.
Currently, there are several registries that pool the data on patients treated with electrochemotherapy; the INSPECT and at least two Italian registries [89]. Some of them
gather data on specific tumor type, melanoma, head and neck tumors, and the other
(INSPECT) on any kind of tumor histology. These data, if appropriately collected, will
help development of electrochemotherapy, and indicate whether drug dosage, route of
administration, or electric pulse treatment needs to be adjusted for higher effectiveness
of electrochemotherapy. Currently all the clinical data report on tumor response, however in future studies the data on patients response are needed in order to indicate the
effect of electrochemotherapy on tumor progression free interval or overall survival.
Only then another meta-analysis can unambiguously demonstrate the differences in the
response rate of different tumor types, based on well synchronized data collection, and
sufficiently long follow-up of patients [90].
Although skin tumors are primarily treated by surgery and radiotherapy, cutaneous
metastases are not rare. Furthermore, improved treatment of metastatic cancer results
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in longer life expectancy, which also results in increased incidence of skin metastases.
Skin metastases can represent important problems for patients and physicians – bleeding
metastasis, local infections, pain, and the consequences of radical treatment by surgery
may lead to disfigurement and greatly impaired quality of life. The treatment of skin metastases is thus becoming increasingly important. Not just improve in patients’ quality of
life but also long-lasting local disease control of cutaneous metastases treated with electrochemotherapy was confirmed in some clinical studies [73,91,92].
The current prevalent use for electrochemotherapy in skin tumors is focused on palliation in patients with numerous skin metastases, or patients who have undergone many
previous treatments. This use is the most documented and investigated, and is also
most supported, e.g. by the NICE guidelines, as we detail in the following section. Electrochemotherapy has also been used in less aggressive non-melanoma types of skin
cancer for treatment of primary tumors, such as basal cell carcinoma. In such cases,
treatment needs to be very efficient to be considered for use in comparison with surgery or radiotherapy. The main use of electrochemotherapy in such cases would be in
areas where there is too little tissue to be able to perform radical resections or where
surgery outcome could lead to greatly diminished patients’ quality of life, or where a
good cosmetic outcome is desired, such as, the head and neck area [93], the cheeks
[94,95], the nose [82,96] or near the eyes [97].
In order to get wide acceptance of any kind of treatment, it has to be included
in (national) guidelines for a specific treatment, authorized by national or international
body, and then it will also enter into the national health system and become eligible for
reimbursement. The acceptance is when the effectiveness of the new therapy is evidence
based, compared to the other ablative techniques that are currently used for cutaneous
tumors/metastases. Therefore only comparative studies will unambiguously demonstrate its effectiveness. Another issue is the acceptance by the patients, morbidity
and hospitalization, where electrochemotherapy may have its advantages over other
ablative techniques.
Currently, electrochemotherapy clinical application is mostly limited to Europe and is
routinely applied in everyday clinical practice in 130 clinical centers (information obtained from IGEA SpA upon request in January 2014). Accounting for differences among
EU countries, electrochemotherapy iscurrently reimbursed by the national health insurances in Switzerland, Austria, Germany, Denmark, Spain, UK, Italy, Portugal,
and Slovenia. Reimbursement activities are ongoing in Poland and France (data obtained from IGEA Srl in January 2014). In most of these countries it has been acknowledged in their treatment guidelines, as well as recommended in European for
the treatment of melanoma [98]. However, except for melanoma, electrochemotherapy
still awaits recognition in guidelines for treatment of other cancers. The exception is
NICE guidelines, where besides melanoma, electrochemotherapy was recognized as treatment option also for the treatment of primary basal cell carcinoma and squamous cell carcinoma [99], and in German guidelines provided by Dermatologic society [100]. Further
advantage of electrochemotherapy is that it can be implemented in developing countries,
where big facilities lake radiotherapy departments are not available, and the cost of
systemic therapy is too high. In such environment, electrochemotherapy could be
the option to help patients with cancer. A further step forward would be also use
of non-chemotherapeutic drugs that do not require specific preparation or handling
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in oncology centers. The first attempt has already been made, the use of calcium,
which has proved its activity in preclinical studies on electrochemotherapy (Table 1)
[31], and the first clinical trial on calcium use in electrochemotherapy has been
initiated (ClinicalTrials.govidentifier: NCT01941901). This approach would give
electrochemotherapy advantage to be implemented outside the oncology centers,
also in private practice of dermatology clinics.
Summarizing, electrochemotherapy is currently accepted for treatment of cutaneous and
subcutaneous metastases and palliation of skin tumors, but lacks evidence for using electrochemotherapy as curative treatment of primary tumors. For this, additional studies need
to be designed and coordinated, which will compare electrochemotherapy with current
standard of care, like surgery and radiotherapy in the case of basal cell carcinoma.
Current developments of electrochemotherapy
Visceral and deep-seated tumors

Electrochemotherapy is now being developed and evaluated for treatment of visceral or
deep-seated tumors [22,23]. In order to do this, several steps need to be accomplished,
including adjustment of the technology and clinical studies that will prove the safety
and effectiveness of the treatment in phase I/II studies. The technology is already being
modified for the treatment of tumors larger than 3 cm in diameter, since the current
technology provides treatment of tumors smaller than 3 cm. The other adjustments are
in the line of safety, predominantly in organs adjacent to the heart, where the delivered
electric pulses can interfere with functioning of the heart. Since the heart is especially
susceptible to induction of life-threatening arrhythmias if electrical pulses are delivered
during the so-called vulnerable period of the ventricles which coincides with T wave in
ECG, synchronization of pulses presents another engineering challenge. The vulnerable
period can be avoided by synchronizing the delivery of the pulses with the QRS complex
of the heartbeat [101-103]. This is an important consideration particularly for clinical trials that are on-going, i.e. for treatment of liver [22], bone [104] and brain metastases
[105], as well as for the treatment of big breast chest wall recurrences [88,106].
Several characteristics make electrochemotherapy a potential candidate for treatment
of visceral and deep-seated tumors. These are the ability to treat volumes with diameters in excess of 3 cm, which is a typical limit for thermal therapies, such as radiofrequency and microwave ablation; the advantage of organ sparing effect, and possibility
of treatment in the vicinity of major blood vessels. Along with these benefits come additional engineering challenges, among them the requirement of complete tumor nodule
coverage by sufficiently high electric field [51,52], that can be achieved by patient specific pre-treatment planning [107], the availability of suitable electrodes for delivery of
electric pulses [108,109], synchronization of pulse delivery with ECG [102,103,110], and
intraoperative guidance of electrode positioning.
The overview of the implementation of electrochemotherapy in treatment of deepseated tumors demonstrates that new electrodes are being developed and used in treatment of various tumor types and locations (Table 3).
Basically three types of electrodes have been developed and are being used:
 The first ones are long needle electrodes that are inserted into the tumor and

surrounding tissue in order to safely cover the tumor and achieve an appropriate
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Table 3 Different types of electrodes developed for electrochemotherapy of visceral and
deep-seated tumors
Type of
electrodes

Location and type of
tumors treated

Institution performing treatment

References/Clinical
trial number

Long needle
(Figure 3)

Metastases of colorectal
tumors in liver bone
metastases soft tissue
sarcomas

Institute of Oncology Ljubljana, Slovenia
Istituto Ortopedico Rizzoli, Bologna, Italy

[22], NCT01264952

Veneto Region Oncology Research
Institute of Padova, Italy

[87]

Cork Cancer Research Center, Ireland

[108], NCT01172860

Copenhagen University Hospital at
Herlev, Denmark

[105], NCT01322100

Endoluminal
(Figure 4)

Colorectal, gastric and
esophageal tumors

Expandable
Brain tumors
“umbrella”
type (Figure 5)

[104]

margin (Figure 3). Such electrodes are being tested for treatment of liver
metastases of colorectal tumors, where safety and effectiveness have been
reported [22]. Such technology can be implemented also for treatment of other
types of tumors, such as hepatocellular carcinoma or cholangiocarcinoma. This
long needle technology is being tested also for treatment of soft tissue
sarcomas [87] and for bone metastases [104], based on solid preclinical
evidence [111]. However it could be implemented also for other large (more
than 3 cm) tumors located deeper under the skin, like in squamous cell head
and neck tumors.
 The second are endoluminal electrodes that are being tested for the treatment of
colorectal cancer but could be used also for the treatment of esophageal tumors
(Figure 4). The ongoing clinical trial in treatment of recurrent colorectal tumors
has included so far just a few patients, but has proven feasibility of such approach
with good antitumor effectiveness [112].
 The third are the electrodes that are aimed at treatment of brain tumors [105,109]
(Figure 5). The electrodes have proven to be suitable for the treatment of the brain
tumors, through the skull. Unfortunately due to slow recruitment the trial was
stopped, but a new one is being prepared (personal communication). Such
electrodes could potentially be used also for treatment of liver tumors, similarly as
percutaneous radiofrequency ablation, with the development of appropriate
monitoring system of electrode guidance into the tumors.

A

B

C

1.8 mm
1.2 mm
Insulating
sleeve
Active tip

Figure 3 Variable geometry needle electrodes available from IGEA Srl. A) Two needle types are
available. Active tip length is either 3 or 4 cm. B) 1.8 mm electrodes with trocar tip used for drilling
into bone. Shown with a bone model. C) 1.2 mm electrodes used during open surgery to treat
liver metastasis.
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C

10 mm

Figure 4 Endoscopic electrode EndoVe. A) CAD model. B) Photography of an actual sample – recommended
voltage 1000 V. C) View of the target lesion during endoscopic procedure.

Conclusion and remaining challenges

A new treatment or medical technology can be adopted in the clinics after it has
proven to be safe and effective. This is the prerequisite, but not sufficient step. It needs
to be established as a practical and safe use among many indications for treatment of
cancer at various stages of the disease. Electrochemotherapy is now at the stage of palliative treatment in most indications, or in the case other treatments have failed. Therefore,
controlled studies will probably not suffice to bring electrochemotherapy along the established ablative techniques (e.g. radiofrequency ablation) or surgery – controlled, randomized clinical trials are needed, but will be difficult to execute. The other option, based on
the current evidence, is that controlled individualized trials will be launched, extending
the treatment indications for also less advanced stages of the disease. In the current situation it is of utmost importance that no serious adverse events are reported, since this
may shed uncertainty on its development. Consistent results regarding effectiveness after
use by clinicians who are not original developers is also a critical step in the growth of a
new treatment.
Electrochemotherapy is in its early phase of clinical acceptance, currently the focus
being on skin tumors and metastasis. Further work is however required. In treating skin
tumors and metastasis electrochemotherapy needs to be compared against current
standard treatments; e.g. for basal cell carcinoma it needs to be compared to radiotherapy and/or surgery. This will also require a five-year follow-up!
In general the body of data needs to be collected in multicenter prospective randomized controlled studies in which response per patient rather than per tumor nodule is
observed. Additionally, focus will need to be on tumor recurrence free interval, and
since electrochemotherapy is a local treatment, quality of life improvement should
probably be one of most important outcomes, rather than patients’ lifespan. Some of

A

B

C

Burr hole

Electrode

Tumor

Figure 5 Retractable brain electrodes. A) Rendering of the electrode in fully retracted state. B) Electrode
in fully extended state. Recommended voltage is 1000 V for the fully extended electrodes. C) Diagram of
the insertion into brain [105].
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these data will also become available from clinical data registries like InspECT, IMI and
GIDO.
The preparation of new/updated Standard Operating Procedures (SOP) will undoubtedly have to deal with differences in responses between differently sized tumors and
different types of tumors. Original SOP and decision tree regarding the number of nodules and route of drug administration (intratumoral or intravenous) were based on the
experience of the developers and not based on controlled studies determining appropriate dose or administration route. While effective and facilitating the advancement of
this treatment modality, further refinement of SOP will be needed to get full acceptance
from the medical community. Data on clinical pharmacokinetics and pharmacodynamics
of bleomycin and cisplatin in electrochemotherapy would also be important to obtain.
Among the studies still needed are dose response evaluations for both intravenous and
intratumoral routes. This may be necessary for several indications particularly relating to
size, location and type of tumor. In a properly designed study different responses to electrochemotherapy with respect to the tumor size could be addressed; as well as the need
for combination of intravenous and intratumoral drug delivery as suggested for efficient
treatment of large tumors.
The other challenge would be also to reduce intensity or extent of muscle contractions in order to eliminate the use of muscle relaxants and consequently also pain during
electrochemotherapy. The first efforts in this direction have been done by suggesting application of high-frequency bipolar electroporation pulses [113].
The remaining challenge is also to address specificity and sensitivity of electrochemotherapy treatment and to determine its therapeutic index. It had not been systematically addressed before how does healthy tissue respond to electrochemotherapy.
In addition, electrochemotherapy can be implemented in combination with surgery
as neoadjuvant treatment. Specifically, with such approach tumors located in surgically
difficult to reach positions, due to the involvement of some critical physiological structures (e.g. nerves and blood vessels) or due to potential damage on organs and functions
(e.g. sight, hearing, speech, eating) can be treated in order to reduce tumor burden before
surgical removal. This approach has already been demonstrated to be useful and effective
[95,114-118]. The downsizing of the tumors can facilitate the surgical intervention, with
long term tumor control, and organ sparing effect. The other approach is that electrochemotherapy would be used after surgical removal of the bulk of the tumor, and electrochemotherapy would be used to treat the remaining tumor mass and achieve appropriate
margins. There is no report on such approach yet, however it has been successfully used
in treatment of sarcoids in horses (personal communication, no reference is available). Either of these approaches needs further developments, which only with time will provide
enough evidence to implement them into a broader clinical practice.
Electrochemotherapy could be used also as concomitant treatment with other treatment modalities. One of the well explored applications is the use of electrochemotherapy as radiosensitizing approach. BLM and CDDP are well known radiosensitizers.
Therefore, electrochemotherapy could, by increased intratumoral accumulation, potentiate radiation response of tumors without normal tissue damage. This was proven
in animal models in several reports, with CDDP and BLM, in single and fractionated irradiation regimen [50,119,120]. However there are only a few clinical reports following
this idea [121-123].
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The other treatment combinations would be in combination with targeted drugs, and
immunostimulatory approaches, either in the form of biologic therapy or in the form
of gene therapy. Some attempts have already been made, predominantly in combination
of electrochemotherapy with gene electrotransfer on preclinical level [49,66-69], however the approach needs clinical verification in clinical trials. It is presumed that such
combined therapy can add a systemic component, by boosting the specific immune response to tumors that was elicited by antigen shedding from tumors after electrochemotherapy. However, there is no clinical evidence that after electrochemotherapy the
non-treated nodules would respond.
In today’s economy additional health economics studies will have to be performed
clearly showing acceptable price for the benefit that electrochemotherapy can bring to
the patients [124]. Electrochemotherapy certainly has potential in this respect as the
drugs currently used are inexpensive and there is the potential for the development of
low cost instruments and electrodes.
Treating deep-seated tumors requires even more effort, time and resources. Even
though the technology of image guided transcutaneous insertion of electrodes is available [125], pretreatment planning development for electrochemotherapy is still in its
early development [126]. Currently electric field distribution prediction is calculated
in 3D models using finite element methods numerical modeling, taking into account different electric properties and increase in conductivity due to electroporation. Optimization of placement of electrodes is thus performed based on criteria
function which for electrochemotherapy requires tumor tissue to be covered with
sufficiently high electric field [127]. Uncertainties in tissue conductivity and exact
positioning of electrodes relative to the target tissue and each other can however
greatly affect tumor treatment outcome [128]. In addition, cell kill based on electrochemotherapy model still needs to be developed in order to be able to predict
tumor treatment outcome. Any approach, which is not covered by the SOP, can
benefit greatly from treatment planning. Although conclusive proof of treatment
planning’s benefit has not yet been established through controlled studies, there
are several indications, that it is beneficial. At the very least, it can serve as tool
for scaling from smaller to larger tumors, since the scaling is non-linear due to
electroporation’s effect on tissue electric properties. Algorithms designed for treatment planning can also be used in novel electrode designs [109].
Achieving acceptance of a new clinical treatment for cancer is a huge project
that takes considerable time, orchestrated efforts and a lot of resources, whereas
biomedical engineers tend to look at medical progress in the short term. Appropriately controlled studies that take all parameters into consideration are a critical
part of bringing a new approach to broad acceptance. Focusing on specific cancer
targets to gain initial acceptance will open up additional treatment options and facilitate acceptance of the therapy. Apart from x-ray all other techniques and treatments needed 20 years or so to gain its place. Needless to say the route is not
always straightforward, nor is it always successful. The regulations in Europe and
USA are quite different, and specific, and costly. However, overall there are no big
differences between the two markets [129,130]. There are new large markets that
will affect usual strategies that companies have in bringing new technologies and
treatments to the patient.
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